Table 2.

Anti-FR and anti-allo responses of transduced T cells from patients in cohort 1 and 2 of the study

	Cohort 2							Cohort 1, median
	Pt. 9	Pt. 10	Pt. 11	Pt. 12	Pt. 13	Pt. 14	Median
Media alone	36	60	34	42	0	19	35	153
Melanoma (FR−)	35	54	28	26	14	27	28	139
IGROV-1 (FR+)	1,375	2,960	8,010	1295	1,340	9,050	2,168	6,501
Allogeneic stimulator PBMCs	2,270	1,555	2,995	5625	>4,320	603	2,633
Autologous PBMCs	210	456	36	140	39	298	175
OKT3	5,784	13,317	9,620	2890	>3,760	>59,000	7,702	7,457

NOTE: T cell reactivity towards the FR tumor antigen and allogeneic stimulator PBMCs was determined by assaying IFN-γ secretion (pg/mL) using ELISA following overnight incubation of Tcells with the targets listed. Plastic-coated anti-CD3 (OKT3) was used as an indicator of maximal T cell response. Transduced T cells from all patients were reactive with FR, and T cells from patients in cohort 2 were reactive with allogeneic PBMCs. Nontransduced Tcells did not respond against IGROV-1, except for patient 14 in whom 548 pg/mL IFN-γ was secreted (data not shown).